Heracles Pharma Seeks to Develop Strategic Partnerships with Pharmaceutical Industry in Pursuit of FDA Approval and Commercialization of X-22 Very Low Nicotine Smoking Cessation Product CLARENCE, N.Y.– XXII, (BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website atwww.heraclespharma.com to highlight the Company’s X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22Read more
- American Rebel (OTCQB: AREB) Sales Grow 79% on Amazon
- GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
- GrowLife Announces Rights Offering to Shareholders for Investment Opportunity for Marketing, Sales and Technology Expansion
- Mace Brand Announces Free Overnight Shipping of Mace Alert 911 to States Affected by Hurricane Florence
- Amazonas Florestal Ltd. Announced Today That the Company Has Appointed a New CFO and Director, Will be Renewing Its Lumber and Carbon Business in Brazil, and Has Completed Its Business Plan for the Colorado Plantations and Lab
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More